首页> 外文OA文献 >Pharmacological treatment option for low Bone Mineral Density and secondary osteoporosis in Anorexia Nervosa:A systematic review of the literature
【2h】

Pharmacological treatment option for low Bone Mineral Density and secondary osteoporosis in Anorexia Nervosa:A systematic review of the literature

机译:神经性厌食症的低骨矿物质密度和继发性骨质疏松症的药理治疗选择:文献综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectiveAlthough there are several evidence-based treatments available to increase Bone Mineral Density (BMD) and reduce fracture risk in aging men and women, there are still uncertainties regarding which treatments are efficacious in reducing lifetime fracture risk in women with Anorexia Nervosa (AN).MethodsMedline, PsychInfo, Embase and the Cochrane Database were searched for English Language Studies. Inclusion criteria were studies of females of any age with AN who received pharmacological treatment with the primary aim to increase BMD or reduce fracture risk. Data were extracted from each study regarding pharmacological treatment and dosage used, BMD and bone formation marker outcomes; and participant characteristics including age, Body Mass Index (BMI), duration of AN, and duration of amenorrhea.Results675 studies were reviewed, of which 19 fit the inclusion criteria and were included in the final review, investigating a total of 1119 participants; 10 of the 19 included studies were double-blind RCTs. The remaining studies consisted of prospective observational studies, a retrospective cohort study, a case-control study and five non-randomised control trials. Bisphosphonates were effective in increasing BMD in adult women with AN, while estrogen administered transdermally resulted in significant increases in BMD in mature adolescents with AN. Administration of oral contraceptives (OC) did not significantly increase BMD in randomised or controlled trials, however, lifetime OC use was associated with higher spinal BMD.ConclusionFuture research should clarify the safety of long-term bisphosphonate use in adult women with AN, and verify that transdermal estrogen replacement increases BMD in women with AN.
机译:目的尽管有几种循证医学疗法可增加老年男性和女性的骨矿物质密度(BMD)并降低骨折风险,但仍存在不确定性,哪些疗法可有效降低神经性厌食症(AN)妇女的终生骨折风险。方法检索Medline,PsychInfo,Embase和Cochrane数据库进行英语研究。纳入标准是对接受药物治疗的任何年龄段AN患者的研究,其主要目的是增加BMD或降低骨折风险。从每项研究中提取有关药物治疗和使用剂量,BMD和骨形成标志物结果的数据;结果675项研究进行了回顾,其中19项符合纳入标准,被纳入最终评价,共调查1119名参与者;研究对象包括年龄,体重指数(BMI),AN持续时间和闭经持续时间。 19项纳入研究中的10项是双盲RCT。其余研究包括前瞻性观察研究,回顾性队列研究,病例对照研究和五项非随机对照试验。双膦酸盐可有效增加成年女性AN的BMD,而经皮给药的雌激素可导致成年AN青春期BMD显着增加。口服避孕药(OC)在随机或对照试验中并未显着增加BMD,但终生OC使用与较高的脊柱BMD相关。透皮雌激素替代会增加AN女性的BMD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号